MAP1LC3A and hepatocellular carcinoma: The results showed that patients with low Axl and high LC3 expression in HCC tissues had 1‐, 3‐, 5‐ and 7‐year OS rates of 96.9%, 88.2%, 82.2% and 41.6%, respectively.